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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Code stroke systems are widely implemented to expedite acute stroke
treatment. Although this system requires considerable resources, so far no reimbursement
has been provided by the Bureau of National Health Insurance (BNHI) in Taiwan. We investi-
gated how often a code stroke was initiated and the percentage of patients treated with intra-
venous (IV) tissue plasminogen activator, and draw attention to the resulting mismatch.
Methods: From January 2010 to September 2011, we prospectively registered all consecutive
code stroke patients. Patient characteristics, including demographic data, medical history,
comorbidity conditions, treatments, and discharge diagnosis were collected, together with
the exact time of onset (or last known normal time) and management. The eligibility of throm-
bolysis for each patient recorded originally on the chart was reviewed retrospectively on the
basis of two sets of criteria, namely, the BNHI reimbursement criteria and the Taiwan Stroke
Society (TSS) guideline.
Results: During the study period, code strokes were activated for 419 patients at an average of
around 20 patients per month. About 57% of code strokes were initiated outside of office hours.
Strokewasdiagnosed in 377 (90%)patients and304 (73%)patients had ischemic strokeor transient
ischemic attack. A total of 42 (10%) patients according to the BNHI reimbursement criteria and
101 (24%) patients by the TSS guideline were eligible for IV thrombolytic therapy. Of all the code
stroke patients, only 49 (12%) were actually treated. Before each additional patient was throm-
bolysed, about eight patients had been evaluated and excluded from treatment.
Conclusion: The majority of code stroke patients were stroke patients; however, most of them
could not be treated with thrombolytic therapy. These findings underscore the need for further
support from the BNHI in order for health-care providers to implement the code stroke systems
successfully.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.have no conflicts of interest relevant to this article.
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14 The protocol is activated byBecause the effectiveness of intravenous (IV) tissue plas-
minogen activator (tPA) in acute stroke treatment is time-
dependent,1 it is advised to minimize the symptoms to
needle time so as to improve treatment outcomes. Many
factors, at both the prehospital and hospital levels, are
associated with delays of thrombolytic therapy in stroke
patients. Code stroke systems are commonly implemented
to shorten the hospital delay in the emergency department
(ED).2e4 However, lack of in-hospital stroke code protocol
might cause up to 18% of eligible stroke patients not
receiving tPA because of an avoidable cause.5 Overall,
implementation of code stroke systems requires consider-
able logistic and human resources.6,7
IV tPA treatment for acute ischemic stroke was approved
in Taiwan in November 2002. In July 2003, the Taiwan
Stroke Society (TSS) released a guideline regarding the use
of IV tPA for acute ischemic stroke in which the exclusion
criteria were modified from the National Institute of
Neurological Disorders and Stroke (NINDS) tPA trial.8 Based
on the guideline, the Bureau of National Health Insurance
(BNHI) started the reimbursement of tPA for acute stroke
treatment in 2004. Data from the Taiwan Stroke Registry,
a nationwide registry enrolling stroke patients from 2006 to
2008, showed that only 1.5% of patients with ischemic
stroke received IV tPA treatment.9 A less restrictive TSS
guideline regarding thrombolytic therapy was released in
2008 to respond to new evidence.10 This updated TSS
guideline expands the patient population suitable for
thrombolytic therapy.
A mismatch between the risks and benefits of managing
acute IV tPA treatment in an emergency settingmay threaten
the IV tPA treatment for acute ischemic stroke in Taiwan. The
greatest concern is legal liability that can arise fromnegative
patient outcomes, especially when the rate of symptomatic
intracerebral hemorrhage after using IV tPA has been found
as high as 10.4% among the Chinese-Taiwanese people.11
Moreover, failures in identifying thrombolysis candidates at
an earlier stage or treating eligible patients have also led to
medical malpractice lawsuits.12 Additionally, up to date, the
BNHI does not provide financial benefits to physicians per-
forming IV tPA therapy nor offer any financial incentives to
hospitals implementing code stroke systems. This may
partially explainwhy IV tPA therapy for acute ischemic stroke
remains underused.13
The primary objective of this study was to explore the
therapeutic yield of an in-hospital code stroke system in
a community hospital by examining how often a code stroke
was initiated and the percentage of patients treated with
IV tPA. Our secondary objective was to underscore the
workload of neurologists caused by the code stroke
protocol.
Patients and methods
The study hospital is a community hospital with an ED
volume of 100,000 patient visits per year. In October 2009,
the ED started a thrombolysis protocol (code stroke) to
guide the evaluation and management of patientstriage nurses or ED physicians when a patient with sus-
pected stroke was identified within 3 hours of onset. The
code stroke activities include establishment of an IV line,
immediate blood testing (complete blood counts,
biochemistries, prothrombin, and activated partial throm-
boplastin times), 12-lead electrocardiography, noncontrast
head computed tomography (CT), determination of blood
pressure in both arms, measurement of body weight, and
notification of the on-call neurologist. A nurse practitioner
on the acute stroke team is responsible for the evaluation
of the National Institutes of Health Stroke Scale (NIHSS) and
assessment of the eligibility for IV tPA treatment. An on-call
neurologist has to examine each patient in person before
the decision to administer thrombolytic therapy.
From January 2010 to September 2011, we prospectively
registered all consecutive patients for whom a code stroke
was activated. Patient characteristics, including demo-
graphic data, medical history, comorbidity conditions,
treatments, discharge diagnosis, and outcomes were
collected following the identical registry protocol as the
nationwide Taiwan Stroke Registry.9 The diagnosis was
made by the treating physicians, based on a clinical
assessment, radiologic findings, and other laboratory tests
as considered relevant by the clinician in charge of the
treatment. Acute stroke was defined as rapid onset of focal
neurological deficits, lasting longer than 24 hours, with no
apparent cause other than vascular origin. Transient
ischemic attack (TIA) required full resolution of symptoms
within 24 hours and no evidence of acute infarct on neu-
roimaging studies. A stroke mimic was diagnosed when the
clinical details did not indicate a vascular etiology, and an
alternate convincing explanation for the symptoms was
established. The exact time of onset (or last known normal
time), arrival at ED, ordering of CT and laboratory tests,
evaluation by neurologists, start of CT scanning, availability
of coagulation results, thrombolysis, and admission to the
intensive care unit (if applicable) were recorded. Eligibility
of thrombolysis for each patient recorded originally on the
chart was reviewed retrospectively according to the BNHI
reimbursement criteria and the 2008 TSS guideline. The
data collection had been approved by the hospital’s Insti-
tutional Review Board.
Median values and interquartile ranges (IQRs) of the time
intervals were used for descriptive statistics because of
their non-normal distributions. While making comparisons,
we used c2 or Fisher exact test for categorical variables and
t test or the Wilcoxon rank-sum test for continuous or
ordinal measures. A value of p< 0.05 (two-sided) was
considered statistically significant.Results
From January 2010 to September 2011, 419 patients were
prospectively accrued to this study through the code stroke
protocol, with an average of around 20 patients per month.
More than half of code stroke patients (239 or 57%) were
initiated outside the office hours. Stroke was diagnosed in
377 (90%) patients and 304 (73%) patients had ischemic
stroke or TIA. Demographic and clinical characteristics for
Table 1 Characteristics of the study patients by diagnosis (NZ 419).
Stroke (nZ 377) Stroke mimics (nZ 42) p
Mean age (y) (SD) 68 (13) 61 (18) 0.009
Men 226 (60) 23 (55) 0.516
Visit outside office hours 214 (57) 25 (60) 0.732
Transported by EMS 151 (40) 19 (45) 0.516
Stroke type
Ischemic stroke 241 (64) d d
Transient ischemic attack 63 (17) d d
Intracerebral hemorrhage 69 (18) d d
Subarachnoid hemorrhage 4 (1) d d
Hospitalization 346 (92) 29 (69) <0.001
Length of stay (d), median (IQR) 7 (4e12) 4 (2e7) 0.001
Data are number (percentage) unless specified otherwise. EMSZ emergency medical service; IQRZ interquartile range; SDZ standard
deviation.
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Table 1. The most frequent stroke mimics included seizure,
toxic-metabolic encephalopathy, and peripheral nerve
disorders (Fig. 1).
Of all the code stroke patients studied (nZ 419), 42
(10%) patients were eligible for IV thrombolytic therapy
based on the current BNHI reimbursement criteria, whereas
101 (42 plus additional 59 patients or 24%) patients were
eligible according to the 2008 TSS guideline (Fig. 2). Most of
those eligible patients according to the BNHI reimburse-
ment criteria received IV tPA except three patients (two
refused thrombolysis and one was not treated because of
an inaccurate medical history provided by a family member
which resulted in delayed CT examination). Of the
remaining 262 patients who were not eligible for IV tPA
based on the BNHI reimbursement criteria, 59 patients
were otherwise thrombolysis candidates using the 2008 TSS
guideline, and 10 of them did receive IV tPA. Overall, 49
(12%) out of 419 code stroke patients received IV tPA.
Notably, before a patient was thrombolysed, about eight
patients had been evaluated and excluded from treatment.
For patients treated with IV tPA, 29% achieved a modi-
fied Rankin scale score of 0 or 1 at 3 months and 8% suffered
a symptomatic intracerebral hemorrhage. Table 2 shows
the characteristics of these patients and outcomes of
thrombolysis. The outcomes were comparable with the
results of other Taiwan studies.9,11 Patients who were notFigure 1 Discharge diagnosis of stroke mimics (NZ 42).eligible for IV tPA according to the BNHI reimbursement
criteria but actually received the treatment tended to be
older and have a higher NIHSS score. Nevertheless, the
efficacy and safety outcomes were not significantly
different between the two groups.
To facilitate comparison with other studies that included
patients with ischemic stroke and TIA as candidates for IV
tPA therapy, we conducted further analysis. Among the 304
patients with ischemic stroke or TIA, 42 (14%) were eligible
for IV tPA according to the BNHI reimbursement criteria.
However, if the 2008 TSS guideline was applied, 101 (33%)
were potentially eligible for tPA. There was a considerable
mismatch between the numbers of thrombolysis candidatesFigure 2 Clinical results of activation of the code stroke
protocol. BNHIZ Bureau of National Health Insurance;
IV tPAZ intravenous tissueplasminogenactivator;TIAZ transient
ischemic attack; TSSZ Taiwan Stroke Society.
Table 2 Baseline characteristics of patients and outcomes of thrombolysis stratified according to eligibility criteria.
Patients eligible according
to BNHI reimbursement criteria
(nZ 39)
Patients eligible according to 2008 TSS
guideline but not fulfilling the BNHI
reimbursement criteria
(nZ 10)
p
Mean age (y) (SD) 65 (12) 75 (17) 0.047
Men 22 (56) 5 (50) 0.737
Baseline NIHSS, median (IQR) 15 (9e20) 22 (10e34) 0.040
mRS 0 or 1 at 3 mo 11 (28) 3 (30) 1.000
SICH 3 (8) 1 (10) 1.000
Data are n (%) unless otherwise specified. BNHIZ Bureau of National Health Insurance; IQRZ interquartile range; mRSZmodified
Rankin scale; NIHSSZ National Institutes of Health Stroke Scale; SDZ standard deviation; SICHZ symptomatic intracerebral hemor-
rhage; TSSZ Taiwan Stroke Society.
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(16%) patients were actually treated with IV tPA. Of these
treated patients, 74% were thrombolysed within 60 minutes
of ED arrival. The median time from door to CT was 14
minutes (IQR: 10.5e21). The median time from door to drug
administration was 53 minutes (IQR: 43e61.5), and the
median time from door to monitored bed was 103 minutes
(IQR: 85e127.5). All the time intervals were within the
recommended goal (25 minutes for door to CT, 60 minutes
for door to drug administration, and 180 minutes for door to
monitored bed) established by the NINDS.15
In the study hospital, attending neurologists provided
inpatient and outpatient services, performed routine and
emergency consultations for adult patients, and carried out
electrodiagnostic studies. Before the era of thrombolytic
therapy, neurologists usually responded to consultation
requests for stroke patients in a less hurry. With the advent
of tPA treatment for acute ischemic stroke, quick access to
neurologic expertise within 15 minutes was recommended
when a potential thrombolytic candidate presented to the
ED.15 After the implementation of the code stroke protocol,
when a code stroke occurred during office hours, neurolo-
gists must interrupt their routine work in order to assist
colleagues in the ED to provide IV tPA. During off-hours, on-
call neurologists need to rush to the hospital within a very
tight time frame. On average, 9 code stroke alerts arose
during office hours and 11 outside office hours each month.Discussion
Our main finding is that the in-hospital code stroke system
has proved itself as an effective way to minimize hospital
delay as shown by the achievement of the time targets set
forth by the NINDS.15 However, the effectiveness was ach-
ieved probably at the expense of adding a considerable
amount of workload to the already very busy neurologists.
The urgent need to arrive to an ED within a very brief
period from notification apparently may have infringed
lifestyle and limited flexibility of practice patterns for
neurologists involved in acute stroke care.
We found that stroke mimics accounted for 10% of all
code stroke activations. A previous study retrospectively
examining database for discharge diagnosis reported that
up to 25% of patients who activated a code stroke were
discharged with a diagnosis other than ischemic stroke orTIA.16 If we likewise consider all nonischemic stroke as
stroke mimics, we had a comparable 27% (115 of 419) stroke
mimics in our study patients.
In this study, more than 70% of code stroke patients were
diagnosed as having an ischemic stroke or TIA. Of these 304
patients, 49 (16%) were actually treated with IV tPA.
A study conducted in a university hospital in Taiwan re-
ported that despite the implementation of an in-hospital
stroke code, only 6% of patients activating the protocol
were treated with IV tPA.17 The majority of patients were
not treated in their study because of fulfillment of one or
more exclusion criteria on the basis of the BNHI reim-
bursement criteria. The therapeutic yield of a code stroke
protocol in Taiwan hospitals was relatively low as compared
with studies conducted in the US (24e27%).18,19 A system-
atic review found an average thrombolysis rate of 38% in
hospitals with an in-hospital code stroke protocol.4
By applying the less-restrictive 2008 TSS guideline, eligi-
bility for tPA in patients with ischemic stroke/TIA increased
from 14% to 33% in our study, but only 16% were treated. A
recent study conducted in a university hospital in Taiwan
showeda similar increaseof eligible patients for tPA from12%
to 27% and a low treatment rate of 6%.20 The major
discrepancy between the BNHI reimbursement criteria and
the 2008 TSS guideline was that the TSS guideline includes
patients older than 80 years, patientswith history of previous
stroke and diabetes mellitus, and patients with minor
(NIHSSZ 4 or 5) or severe (NIHSS > 25) stroke as eligible for
thrombolysis treatment, though they may not be covered by
the National Health Insurance. These patients had to pay the
cost of IV tPA treatment out of pocket. The discrepancy
between the eligibility criteria could contribute to the low
treatment rate. Patients withminor stroke tended to opt out
rather than taking the risk of bleeding, which is inherent in
thrombolytic therapies. Another potential explanation for
the low treatment rate is the neurologist’s preference
toward the more restrictive BNHI reimbursement criteria to
avoid protocol violations with resulting unfavorable patient
outcomes or even lawsuits.
Our data also showed that the on-call neurologists had to
travel to and from the hospital during off-hours around
11e12 times per month. Moreover, the low therapeutic
yield (one IV tPA-treated patient for every nine patients
evaluated) would have diluted the financial benefits asso-
ciated with thrombolysing a patient, not to mention that
there are no financial benefits to the treatment according
446 S.-F. Sung, M.-C. Tsengto the current BNHI reimbursement policy. Although prac-
ticing medicine is much more about appropriate medical
care and altruism than financial gain, the current system in
Taiwan would have driven neurologists into other subspe-
cialties and away from acute stroke care.
Physician reimbursement for the evaluation and treat-
ment of acute stroke has been relatively low in both the US
and Canada.21 In 2005, the US Centers for Medicare &
Medicaid Services created diagnosis-related group code 559
to increase reimbursement for stroke patients treated with
IV tPA. With the increased payment to hospitals that
provided acute stroke care, a new economically favorable
cost-reimbursement ratio has been established.22 From
2005 to 2009, the treatment rates of IV tPA for acute
ischemic stroke have been doubled.13
Our findings are limited, however, by the observational
anddescriptivenatureofhospital-basedevidence.Wedidnot
have statistical power to detect a difference in the outcomes
of thrombolysis between patients who were eligible accord-
ing to the BNHI reimbursement criteria and those who were
eligible solely by the 2008 TSS guideline owing to the small
patient numbers. This study was also limited by the correct-
ness of discharge diagnosis, particularly for patients without
hospitalization. Furthermore, we did not investigate the real
timespentonevaluatingpatientsandon traveling toandfrom
the hospital by on-call neurologists.
In sum, although Taiwan’s National Health Insurance
system has been well acknowledged for its many merits, two
“mismatches” regarding the administration of thrombolytic
therapy are still pending to be resolved. The first is the
discrepancy in exclusion criteria between the 2008 TSS
guideline and the reimbursement criteria adopted by the
BNHI. Expanding the BNHI reimbursement coverage of IV tPA
treatment should increase thenumber of stroke patientswho
may benefit from IV tPA therapy. The second mismatch is
caused by the substantial workload required for adminis-
tration of IV tPA in general, or implementation of the code
stroke system in particular. If the delivery of thrombolytic
therapy and corresponding reimbursement are not balanced
or properly aligned, neurologists may be frustrated (if not
burned out) by treating acute stroke patients.
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